A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vertex Pharmaceuticals Incorporated

Criteria

Inclusion Criteria:

• Adult patients 18 to 75 years of age with active RA

• Must have been taking MTX for at least 6 months

• No concurrent DMARD treatment (other than a stable dose of MTX)

Exclusion Criteria:

• Planned major surgery (e.g., joint replacement) within the duration of the treatment period of the study

• Treated with intra-articular injections of corticosteroids within 28 days prior to Day 1